Harold Robert Meyer – The ADD Resource Center
Reviewed: September 11, 2026 Published: September 24, 2026
Two different things travel under one label — a peer-reviewed construct and a clinical term that outran its evidence. Untangling them is what changes the chart, the prescription, and the conversation with a patient who’s already decided what they have.
A patient names it before you do. They found “Rejection Sensitive Dysphoria” online, recognized every line of it, and arrived expecting it on the chart. The term is doing real work — it’s just not the work of a diagnosis. Untangling what RSD actually refers to, what’s been studied recently, and what remains asserted rather than shown is the difference between a useful formulation and a label that forecloses the real differential.
Key Takeaway: Rejection Sensitive Dysphoria describes a real, intensely felt pattern that overlaps heavily with the peer-reviewed construct of rejection sensitivity and with ADHD’s broader emotional dysregulation. It is not a DSM or ICD diagnosis, has no validated instrument of its own, and — per a 2024 critical appraisal from the clinician who popularized the term — its leading pharmacologic treatment may be ahead of its evidence.
Key Findings:
- Rejection sensitivity — the tendency to anxiously expect, readily perceive, and intensely react to rejection — is a 1996 peer-reviewed construct (Downey & Feldman); “RSD” is a separate, later clinical term for its ADHD-specific intensity, popularized by psychiatrist William Dodson beginning around 2016 and not itself peer-reviewed at origin.
- A 2026 qualitative study of ADHD adults (Rowney-Smith et al., PLOS ONE) identified three consistent themes — withdrawal, masking, and bodily sensations — adding texture current screening tools don’t capture.
- Adults with ADHD show markedly elevated emotional dysregulation compared to controls, with emotional lability the most affected dimension (Beheshti, Chavanon & Christiansen, 2020, meta-analysis, Hedges’ g = 1.17).
- Dodson himself, with Modestino, published a 2024 editorial questioning whether alpha-2A agonists — the medication class most associated with treating RSD — are being prescribed for it ahead of adequate supporting evidence.
Two lineages, one label
“Rejection sensitivity” and “Rejection Sensitive Dysphoria” are often used interchangeably, but they have different origins and different evidentiary footing. Rejection sensitivity is the older, peer-reviewed construct: a disposition to anxiously expect, readily perceive, and overreact to rejection, first operationalized by Downey and Feldman in 1996 and studied since across depression, social anxiety, and — more recently — ADHD (Müller, Mellor & Pikó, 2024, found ADHD symptom severity positively associated with rejection sensitivity in college students). “RSD” is the newer, ADHD-specific clinical term, describing the same reactivity at higher intensity and speed, with a shame-toned quality. It was popularized by psychiatrist William Dodson through clinical writing beginning around 2016, not through a peer-reviewed diagnostic trial. Both describe real distress. Only one has an evidence base built the way a diagnosis requires.
Where it actually sits diagnostically
RSD is not in the DSM-5-TR or ICD-11 as its own category. It hasn’t cleared the bar a new disorder needs: an agreed symptom set, diagnostic reliability across clinicians, and evidence that it adds something existing diagnoses don’t already cover. Two things are worth knowing precisely here. First, rejection sensitivity does appear inside an existing DSM-5-TR criterion — the atypical-features specifier for a depressive episode lists “a longstanding pattern of interpersonal rejection sensitivity” as a defining feature, so the construct has formal diagnostic standing, just not under the name RSD and not tied to ADHD. Second, ICD-11 names emotional dysregulation as a commonly associated feature of ADHD without formalizing rejection sensitivity as a distinct entity. In practice, an RSD-shaped presentation is usually better explained by ADHD’s own emotional-dysregulation features, social anxiety, depression (particularly the atypical subtype), PTSD, or autism — and figuring out which is driving it is the actual clinical task.
What the newest evidence adds
The 2026 Rowney-Smith et al. focus-group study is the most direct recent addition: participants described rejection sensitivity as inseparable from masking (suppressing the reaction to appear unaffected) and from physical sensations — nausea, chest tightness, a sense of paralysis — that current self-report screeners don’t ask about. That maps onto the larger meta-analytic picture: Beheshti and colleagues (2020) found adults with ADHD show large, consistent elevations in emotional dysregulation relative to controls, with emotional lability the most affected dimension — and Faraone and colleagues (2019), in a widely cited practitioner review, argued emotional impulsivity and deficient emotional self-regulation may be specific enough to ADHD to function as diagnostic features in their own right, while still stopping short of endorsing “RSD” as a discrete syndrome. Read together, the field is converging on emotional dysregulation as a core ADHD feature faster than it is converging on RSD as a named condition within it.
Evaluation, treatment, and a genuine open question
There is no validated RSD questionnaire; clinicians document it descriptively — “clinically significant rejection sensitivity contributing to functional impairment” — within whatever diagnosis actually governs the case, sometimes alongside a rejection-sensitivity measure used dimensionally. Treatment follows the same logic: optimize ADHD treatment where ADHD is the driver, and add CBT for threat interpretation and avoidance or DBT skills for the speed and intensity of the reaction, with trauma-focused work where triggers are clearly conditioned. The genuinely current question is pharmacologic. Alpha-2A agonists (guanfacine, clonidine) are widely prescribed off-label for RSD specifically — and in 2024, Dodson and Modestino published a pointed editorial in Current Psychopharmacology asking whether that practice has outrun its evidence, given the absence of controlled trials targeting RSD as an outcome. That two-sided picture — plausible mechanism, real clinical use, thin controlled evidence — is the honest current state, not a settled answer either way.
The billing reality
Because RSD isn’t an ICD-10-CM diagnosis, it cannot be billed as a standalone condition. Coverage runs through the diagnostic evaluation and psychotherapy codes tied to the governing diagnosis — ADHD, an anxiety disorder, depression, PTSD. Documenting functional impairment, not the word “RSD,” is what supports medical necessity.
A Note for Clinicians and Prescribers
Patients increasingly arrive self-identified as having “RSD” from social media or our own reader-facing content, expecting the term on the chart. It’s worth validating the mechanism as real and researched under other names, while keeping the differential open — atypical depression, social anxiety, PTSD, and autism all produce a similar picture — and documenting functional impairment against whichever diagnosis actually governs treatment and billing. Before adding an alpha-2A agonist specifically for rejection sensitivity, it’s worth weighing Dodson and Modestino’s own 2024 caution against the current absence of controlled trials for that specific indication.
The next step
If “RSD” is the only word you’ve had for this, bring the pattern, not the label, to your next appointment: how fast it hits, what it feels like in your body, what you do afterward. ADDRC covers the everyday experience of this pattern — recognizing it, managing it day to day, and telling it apart from ADHD’s other symptoms — in Defining Rejection Sensitive Dysphoria (RSD) as It Relates to ADHD, Managing Rejection Sensitive Dysphoria: 7 Evidence-Based Strategies, and RSD and ADHD: Do You Have Both, One, or Neither? This piece is the research layer underneath those.
Synopsis
Rejection Sensitive Dysphoria (RSD) describes a real, well-recognized pattern of intense, fast-onset distress after perceived rejection or criticism, common in ADHD — but it is not a DSM or ICD diagnosis, has no validated instrument, and its leading pharmacologic treatment (alpha-2A agonists) was publicly questioned as ahead of its evidence by the term’s own popularizer in 2024. This piece distinguishes the peer-reviewed rejection-sensitivity construct (Downey & Feldman, 1996) from the newer clinical term “RSD,” incorporates a 2026 qualitative study and the current emotional-dysregulation literature, and lays out how the pattern is actually evaluated, treated, documented, and billed.
Topic: Emotional Health / RSD · Audience: Clinicians & Prescribers; Sophisticated Adult Readers with ADHD Keywords: rejection sensitive dysphoria, rejection sensitivity, emotional dysregulation, alpha-2A agonists, DSM
Bibliography
American Psychiatric Association. (2022). Diagnostic and statistical manual of mental disorders (5th ed., text rev.). https://doi.org/10.1176/appi.books.9780890425787
Beheshti, A., Chavanon, M.-L., & Christiansen, H. (2020). Emotion dysregulation in adults with attention deficit hyperactivity disorder: A meta-analysis. BMC Psychiatry, 20, 120. https://doi.org/10.1186/s12888-020-2442-7 · Free full text (PMC)
Dodson, W. W., & Modestino, E. J. (2024). Have we placed the cart before the horse by using alpha-2A agonists to treat rejection sensitivity dysphoria in ADHD? Current Psychopharmacology, 12(1), E050424228696. https://doi.org/10.2174/0122115560297397240404071044
Downey, G., & Feldman, S. I. (1996). Implications of rejection sensitivity for intimate relationships. Journal of Personality and Social Psychology, 70(6), 1327–1343. https://doi.org/10.1037/0022-3514.70.6.1327
Faraone, S. V., Rostain, A. L., Blader, J., Busch, B., Childress, A. C., Connor, D. F., & Newcorn, J. H. (2019). Practitioner review: Emotional dysregulation in attention-deficit/hyperactivity disorder — implications for clinical recognition and intervention. Journal of Child Psychology and Psychiatry, 60(2), 133–150. https://doi.org/10.1111/jcpp.12899
Müller, V., Mellor, D., & Pikó, B. F. (2024). Associations between ADHD symptoms and rejection sensitivity in college students: Exploring a path model with indicators of mental well-being. Learning Disabilities Research & Practice, 39(4), 223–236. https://doi.org/10.1177/09388982241271511
Rowney-Smith, A., Sutton, B., Quadt, L., & Eccles, J. A. (2026). The lived experience of rejection sensitivity in ADHD — A qualitative exploration. PLOS ONE, 21(1), e0314669. https://doi.org/10.1371/journal.pone.0314669 · Free full text (PMC)
Resources
- Defining Rejection Sensitive Dysphoria (RSD) as It Relates to ADHD — ADDRC
- Managing Rejection Sensitive Dysphoria: 7 Evidence-Based Strategies for Emotional Resilience — ADDRC
- Rejection Sensitive Dysphoria in Children: Why Your Child Takes Everything Personally — ADDRC
- RSD and ADHD: Do You Have Both, One, or Neither? — ADDRC
- What is RSD? The Condition Often Linked with ADHD — ADDRC
- CHADD: Rejection Can Be More Painful with ADHD — CHADD
- Cleveland Clinic: Rejection Sensitive Dysphoria (RSD) — Cleveland Clinic
About the Author
Harold Robert Meyer founded The ADD Resource Center in 1993 and has spent more than thirty years translating the lived experience of ADHD into practical guidance for individuals, families, and the clinicians and educators who work with them. He co-founded CHADD of New York in 1989 and went on to serve on CHADD National’s board and executive committee, including as Vice President of Finance. He was later elected to lead the Institute for the Advancement of ADHD Coaching. An author and international speaker, he has presented at the American Psychiatric Association Annual Meeting, CHADD national and local conferences, NYU Langone, Mount Sinai Medical Center, and Weill Cornell Medical College. Reach him at [email protected].
📚 Come back often — we add new evidence-based ADHD resources daily.
The ADD Resource Center [email protected] · +1 (646) 205-8080 · 127 West 83rd St., Unit 133, Planetarium Station, New York, NY 10024-0840 USA
X · LinkedIn · Facebook · Substack · Newsletter
✉️ Please consider the environment before printing.
Our content is educational and informational only – not medical, legal, financial, or other professional advice, nor a substitute for it, and should not be relied on as such. We strive for accuracy, but errors or omissions occur and information becomes outdated. Some content and images may be created with AI assistance and, though reviewed before publication, may contain inaccuracies. Our screening tools are not diagnostic instruments. Verify independently and consult a qualified professional before acting on anything here.
In the USA and Canada, call or text 988 anytime for free mental health and suicide prevention support, or call 911 if someone is in immediate danger. The ADD Resource Center is independent from these services and is not liable for any actions taken by you or by these services.
Rejection Sensitive Dysphoria (RSD) is recognized by many providers but is not in the DSM.
Under GDPR and CCPA, you may request access to, correction of, or deletion of your personal data at [email protected].
© 2026 The ADD Resource Center. All rights reserved.